论文部分内容阅读
目的:评价消癌平注射液在恶性肿瘤化疗中增效减毒作用。方法:采用Cochrane循证医学系统评价方法,检索消癌平注射液联合化疗治疗恶性肿瘤的随机对照试验,筛选合格试验进行文献质量评价,采用Rev Man 4.2和Stata12.0进行统计学处理。结果:共纳入9篇符合纳入标准的文献,Jadad评分均小于3分。Meta分析结果显示:纳入文献不存在发表偏倚;与单纯化疗相比,消癌平注射液联合化疗能够提高化疗近期疗效的有效率[OR=1.88,95%CI(1.31,2.71)],提高生活质量的改善率[OR=3.36,95%CI(2.19,5.15)],降低白细胞下降的发生率[OR=0.48,95%CI(0.31,0.73)],其差异均有统计学意义(均P<0.01);消癌平注射液联合化疗治疗后的血红蛋白和血小板下降发生率总体OR值分别为0.65、0.72,95%CI分别为0.34~1.21、0.40~1.29,差异均无统计学意义(均P>0.05)。结论:消癌平注射液对化疗治疗恶性肿瘤具有协同增效、提高生活质量和减轻白细胞毒性反应等作用。由于纳入研究的质量偏低,尚需要高质量、设计严谨、多中心的随机对照试验进一步评价。
Objective: To evaluate the efficacy of Xiaochang injection in reducing the toxicity of chemotherapy in malignant tumors. Methods: Cochrane evidence-based medical system evaluation method was used to search for randomized controlled trials of Xiao-Jin-Ping Injection combined with chemotherapy in the treatment of malignant tumors. The eligible trials were screened for literature quality evaluation and the data were analyzed by using Rev Man 4.2 and Stata12.0. Results: A total of 9 eligible articles were included, with Jadad scores less than 3. Meta-analysis showed that there was no publication bias in the inclusion documents. Compared with chemotherapy alone, combination of Xiaofanping injection and chemotherapy could improve the efficacy of chemotherapy in the near future [OR = 1.88,95% CI (1.31,2.71)], and improve life (OR = 3.36,95% CI (2.19,5.15)] and the incidence of leukopenia (OR = 0.48,95% CI (0.31,0.73)] were significantly lower (all P <0.01). The overall OR of hemoglobin and thrombocytopenia after combination of Xiaowanping injection and chemotherapy was 0.65,0.72 and 95% CI were 0.34-1.21 and 0.40-1.29, respectively, with no significant difference (both P> 0.05). Conclusion: Xiaochangping injection has synergistic effect on chemotherapy for malignant tumor, improving quality of life and alleviating the toxicity of leucocyte. Because of the low quality of the included studies, further evaluation is needed with high-quality, well-designed, multicenter randomized controlled trials.